课题基金 / 基金详情

项目摘要

项目成果

Qizhi Tang的其他基金

相似基金

相关文献

中文摘要
翻译
摘要/概要 核心B:流式细胞术和细胞分选核心。导致1型和2型糖尿病的事件的发生和进展 2型糖尿病伴随着受试者体内多种细胞类型的改变。表征, 通过这些仪器,DRC研究者能够追踪和分离这些细胞群, 流式细胞术和细胞分选核心的专业知识。 目的:流式细胞术和细胞分选核心帮助研究人员进行研究, 分散的细胞中的分子标志物的表征和/或基于这些标志物的细胞分离。 Core提供以下服务,目前平均访问5501次,细胞计数/分选9419次 来自20个DRC实验室的143名研究人员的研究时间: 1.流式细胞仪五台高速多激光流式细胞仪和分析程序,具有高度的 补充能力可满足DRC对电池表征的需求。 2.细胞分选。六台高速多激光荧光激活细胞分选仪使DRC研究人员能够 分离细胞群,然后可以对其进行广泛的分子表征,或者可以将其重新引入 宿主动物来检查这些细胞对疾病进展的影响。 3.信息和培训。核心培训调查人员如何正确使用设备,并提供 关于技术应用的建议。 对DRC社区的好处:核心通过为DRC研究人员提供 获得超出个人能力的先进技术和运营专业知识 实验室维护。39个NIH资助的项目和31个其他糖尿病相关项目,每年总计13,640,397美元 直接成本得益于实际和经济地获得这一急需的技术。 技术开发:很少有实验室拥有开发最先进能力的资源, 充分发挥仪器的潜力。DRC的支持使一名核心工作人员能够 每周有一天开发DRC执行委员会认为需要的先进能力, 刚果民主共和国调查员。例如,先进仪器上的新光谱分析功能 尚未公开的,现在正在核心开发,以提高准确性和数量, 可用于分析疾病进展期间特定细胞群体的通道。 在过去的三年里,该核心已成功地与其他UCSF细胞计数和细胞 分拣设施,以协调设备采购,扩大仪器访问,并提高工作人员 空房的一个强大的共同支付机制,确保刚果民主共和国的支持是引导糖尿病研究, 机构范围的核心,提供更大程度的补充工具, 通过在更大的用户基础上支付核心维护和人员成本来降低成本。
英文摘要
Abstract/Summary Core B: Flow Cytometry & Cell Sorting Core. The initiation and progression of events leading to type 1 and type 2 diabetes is accompanied by alterations in multiple cell types within the subject. Characterization, tracking and isolation of those cell populations by DRC investigators are enabled by the instruments and expertise available in the Flow Cytometry & Cell Sorting Core. Purpose: The Flow Cytometry & Cell Sorting Core assists investigators whose research requires the characterization of molecular markers in dispersed cells and/or the isolation of cells based on those markers. The Core provides the following services that is currently averaging 5501 accesses and 9419 cytometry/sorting hours by 143 researchers in 20 DRC laboratories: 1. Flow Cytometry. Five high-speed, multi-laser flow cytometers and analysis programs with highly complementary capabilities are available to meet DRC demand for cell characterization. 2. Cell Sorting. Six high-speed, multi-laser fluorescence activated cell sorters enable DRC investigators to isolate cell populations that can then be extensively characterized molecularly or that may be re-introduced to host animals to examine the effect of those cells on disease progression. 3. Information and Training. The Core trains investigators on the proper use of equipment and provides advice on the application of the technology. Benefits to DRC Community: The Core accelerates diabetes research by providing DRC investigators with access to advanced technologies and operational expertise that are beyond the abilities of individual laboratories to maintain. 39 NIH-funded and 31 other diabetes-related projects totaling $13,640,397 annual direct costs have benefited from the practical and economic access to this highly needed technology. Technology Development: Few laboratories have the resources to develop the most advanced capabilities to realize the full potential of the instruments. Support from the DRC enables one Core staff member to spend up to one day a week developing advanced capabilities that the DRC Executive Committee finds to be required by large numbers of DRC investigators. For example, new spectral analysis capabilities on advanced instruments not yet publicly available are now being developed in the Core to increase the accuracy and number of channels available for the analysis of specific cellular populations during disease progression. In the past three years, this Core has been successfully consolidated with other UCSF cytometry and cell sorting facilities to coordinate equipment procurement, expand instrument access and enhance staff availability. A robust co-pay mechanism ensures that DRC support is channeled to diabetes research in an institution-wide Core that provides access to a much greater degree of complementary instrumentation at lowered costs through the defraying of Core maintenance and personnel costs over a larger user base..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
"Regulatory 'T' Cell Control of Autoimmune Diabetes".
"Regulatory 'T' Cell Control of Autoimmune Diabetes".
"Regulatory 'T' Cell Control of Autoimmune Diabetes".
"Regulatory 'T' Cell Control of Autoimmune Diabetes".
海外基金